Article Details

AstraZeneca moves to acquire McMaster-supported Fusion Pharmaceuticals for $2.4 billion (US)

Retrieved on: 2024-03-19 21:38:49

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca moves to acquire McMaster-supported Fusion Pharmaceuticals for $2.4 billion (US). View article details on hiswai:

Excerpt

Led by CEO John Valliant, Fusion, which develops next-generation precision cancer medicines will become a wholly owned subsidiary of AstraZeneca and ...

Article found on: brighterworld.mcmaster.ca

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up